Patent application number | Description | Published |
20090012123 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient - As a result of intensive studies for the purpose of finding a new medicinal use of an indazole derivative, it was found that an indazole derivative inhibits glutamate-induced retinal neuronal cell death in rat fetal retinal neuronal cells, in other words, the indazole derivative acts directly on the retinal neuronal cells and exhibits an effect of protecting retinal neuronal cells. Accordingly, the indazole derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage or retinal damage. | 01-08-2009 |
20090170887 | Novel indazole derivative having spiro ring structure in side chain - An object of the present invention is to create a novel indazole derivative having a spiro ring structure in a side chain, which is useful as a pharmaceutical, and to find a new pharmacological activity of the derivative. The present invention compound is represented by the general formula [I] and has an excellent Rho kinase inhibitory activity. In the formula, the ring X represents a benzene ring or a pyridine ring; R | 07-02-2009 |
20100056522 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT - An object of the present invention is to find a novel pharmacological effect of a compound having an HDAC inhibitory effect. The compound having an HDAC inhibitory effect of the invention has an excellent effect of cell morphological change on trabecular meshwork cells and/or effect of intraocular pressure reduction, and is therefore useful as a preventive and/or therapeutic agent for a disease considered to be associated with aqueous humor circulation and/or intraocular pressure, particularly as a preventive and/or therapeutic agent for glaucoma or ocular hypertension. | 03-04-2010 |
20100093770 | THERAPEUTIC AGENT FOR GLAUCOMA CONTAINING ADENOSINE DERIVATIVE AS ACTIVE INGREDIENT - A method for treating glaucoma or ocular hypertension comprising administering to a patient a pharmacologically effective amount of a compound represented by the following (1) or a salt thereof: | 04-15-2010 |
20120010288 | Method for protecting a retinal neuronal cell - A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient. | 01-12-2012 |
20130109646 | METHOD FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION WITH AN ADENOSINE DERIVATIVE | 05-02-2013 |
20140018350 | COMBINATION OF SULFONAMIDE COMPOUND AND TAFLUPROST - The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with tafluprost, their intraocular pressure lowering effects are complemented and/or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug. | 01-16-2014 |
20140018396 | COMBINATION OF SULFONAMIDE COMPOUND - The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and/or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug. | 01-16-2014 |